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Abstract
Objective:  To  evaluate  phenylalanine  plasma  proﬁle  in  preterm  newborns  fed  different  human
milk diets.
Methods:  Twenty-four  very-low  weight  preterm  newborns  were  distributed  randomly  in  three
groups  with  different  feeding  types:  Group  I:  banked  human  milk  plus  5%  commercial  forti-
ﬁer  with  bovine  protein,  Group  II:  banked  human  milk  plus  evaporated  fortiﬁer  derived  from
modiﬁed  human  milk,  Group  III:  banked  human  milk  plus  lyophilized  fortiﬁer  derived  from  mod-
iﬁed  human  milk.  The  newborns  received  the  group  diet  when  full  diet  was  attained  at  15  ±  2
days.  Plasma  amino  acid  analysis  was  performedon  the  ﬁrst  and  last  day  of  feeding.  Comparison
among  groups  was  performed  by  statistical  tests:  one  way  ANOVA  with  Tukey’s  post-test  using
SPSS  software,  version  20.0  (IBM  Corp,  NY,  USA),  considering  a  signiﬁcance  level  of  5%.
Results:  Phenylalanine  levels  in  the  ﬁrst  and  second  analysis  were,  respectively,  in  Group  I:
11.9  ±  1.22  and  29.72  ±  0.73;  in  Group  II:  11.72  ±  1.04  and  13.44  ±  0.61;  and  in  Group  III:  11.3
±  1.18  and  15.42  ±  0.83  mol/L.
Conclusion:  The  observed  results  demonstrated  that  human  milk  with  fortiﬁers  derived  from
human milk  acted  as  a  good  substratum  for  preterm  infant  feeding  both  in  the  evaporated  or
the  lyophilized  form,  without  signiﬁcant  increases  in  plasma  phenylalanine  levels  in  comparison
to  human  milk  with  commercial  fortiﬁer.
©  2014  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  
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Fenilalanina  plasmática  em  recém-nascidos  pré-termo  alimentados  com  diferentes
dietas  de  leite  humano
Resumo
Objetivo:  Avaliar  o  perﬁl  plasmático  do  aminoácido  fenilalanina  em  recém-nascidos  pré-termo
alimentados com  diferentes  dietas  de  leite  humano.
Métodos:  Foram  estudados  24  recém-nascidos  pré-termo  de  muito  baixo  peso,  distribuídos  em
três  grupos  com  diferentes  dietas:  Grupo  I:  leite  humano  de  banco  com  5%  de  aditivo  comercial
para  leite  humano  com  proteína  de  origem  bovina  (LHB-AC);  Grupo  II:  leite  humano  de  banco
com  aditivo  de  leite  humano  modiﬁcado  evaporado  (LHB-E);  e  Grupo  III:  leite  humano  de  banco
com  aditivo  de  leite  humano  modiﬁcado  lioﬁlizado  (LHB-L).  Os  recém-nascidos  receberam  a
dieta  deﬁnida  para  o  grupo  quando  alcanc¸aram  dieta  plena  por  15±2  dias.  A  análise  do  aminoá-
cido  plasmático  foi  feita  no  primeiro  e  último  dias  da  dieta.  A  comparac¸ão  entre  os  grupos  foi
realizada  por  meio  do  teste  ANOVA  de  uma  via,  seguido  pelo  pós-teste  de  Tukey,  utilizando-se  o
software  SPSS,  versão  20.0  (IBM  Corp,  NY,  EUA),  e  considerando  um  nível  de  signiﬁcância  de  5%.
Resultados:  As  concentrac¸ões  plasmáticas  do  aminoácido  fenilalanina  na  primeira  e  segunda
análises foram,  respectivamente,  no  Grupo  I  (LHB-AC)  11,9±1,22  e  29,72±0,73;  no  Grupo  II
(LHB-E)  11,72±1,04  e  13,44±0,61;  e  no  Grupo  III  11,3±1,18  e  15,42±0,83  umol/L.
Conclusão: Os  resultados  encontrados  demonstram  que  o  leite  humano  com  aditivos  do  próprio
leite humano  comportou-se  como  um  bom  substrato  para  alimentac¸ão  do  recém-nascido  pré-
termo,  tanto  na  forma  evaporada  como  lioﬁlizada,  sem  levar  a  aumentos  signiﬁcativos  na
concentrac¸ão  plasmática  de  fenilalanina  em  comparac¸ão  ao  leite  humano  com  aditivo  co-
mercial.
©  2014  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  
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The  superiority  of  human  milk  (HM)  feeding  in  preterm
newborns (PNs)  is  well  documented.  HM  has  an  impor-
tant impact  on  brain  growth  and  development,  even  when
it does  not  promote  great  weight  gain,  supporting  the
concept that  the  optimal  postnatal  growth  of  PNs  is  not  yet
known.1--5
Regarding  the  supply  of  proteins,  not  only  the  quantity
but also  the  quality  is  important  for  proper  growth.  The
amino acid  composition  of  formulas  and  additives  to  human
milk using  bovine  protein  has  reduced  quality  in  relation  to
HM,6--9 which  is  considered  the  gold  standard.
The  protein  fraction  of  cow’s  milk  has  a  predomi-
nance of  casein,  which  has  high  content  of  the  amino
acid phenylalanine.10 Although  it  is  an  essential  amino  acid
in children  receiving  cow’s  milk  protein,  plasma  levels  of
this amino  acid  are  high  (close  to  those  associated  with
metabolism defects).11--13
The  increased  intake  and  plasma  levels  of  phenylala-
nine results  in  the  inhibition  of  the  enzyme  tyrosinase,
and subsequent  conversion,  through  hydroxylation,  of  phen-
ylalanine into  tyrosine,  increasing  tyrosine  availability.
This increase  can  cause  a  deleterious  effect  on  brain
development, leading  to  consequences  such  as  sleep  distur-
bance, memory  deﬁcits,  and  attention  and  concentration
deﬁcits.14--17
While  the  optimal  nutrition  for  PNs  is  unknown,  neona-
tologists should  be  committed  to  what  appears  to  be
ideal, which  does  not  result  in  changes  in  the  short-term,
and provides  better  long-term  development.  In  this  con-
text, supplementing  HM  with  an  additive  containing  a
t
f
arotein  homologous  to  that  of  HM  appears  to  be  a  suitable
lternative for  protein  supply,  while  maintaining  safe  plasma
evels of  phenylalanine.18--20
Considering  this  hypothesis,  this  study  aimed  to  com-
aratively analyze  plasma  levels  of  phenylalanine  in  PNs
ed banked  human  milk  (BHM)  plus  the  commercial  additive
M85 (Fortiﬁed  Milk  85,  Nestlé,  São  Paulo,  Brazil)  and  PNs
ed with  BHM  plus  an  additive  derived  from  the  HM  itself,
fter removal  of  fat  and  lactose  in  evaporated  or  lyophilized
orms.
ethods
fter  approval  of  the  Federal  University  of  Mato  Grosso  do
ul (UFMS)  Research  Ethics  Committee  (Res.  17/2006),  a
on-blinded randomized  clinical  trial  was  performed  from
008 to  2010,  in  the  neonatology  section  of  the  Núcleo  do
ospital Universitário  (NHU)  of  UFMS  (Universidade  Federal
e Mato  Grosso  do  Sul,  Campo  Grande,  MS,  Brazil).
A  total  of  24  PNs  hospitalized  in  the  neonatal  sector,  of
oth genders,  were  studied  after  being  divided  into  three
roups. Each  group  received  a  different  HM-based  diet.  The
roups were  compared  for  plasma  levels  of  phenylalanine.
o conﬁrm  that  the  groups  had  similar  characteristics  and
hat the  difference  in  plasma  phenylalanine  levels  was  asso-
iated with  the  diet  they  received,  the  PNs  were  compared
egarding gender,  gestational  weight/age,  respiratory  dis-
ress syndrome  (RDS),  gestational  age,  birth  weight,  start  of
eeding, volume,  calories,  early  minimal  enteral  nutrition,
nd days  on  ventilator.
The diets  offered  to  each  group  were:
5 Thomaz  DM  et  al.
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Figure  1  Chart  showing  serum  phenylalanine  levels  in  each
of the  PN  feeding  regimens  used  in  this  study  and  according  to
the time  of  analysis.  Each  symbol  represents  the  mean  and  the
bar represents  the  standard  error  of  the  mean.
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Group  I:  PNs  fed  BHM,  plus  5%  commercial  additive  FM  85®
(Nestlé,  São  Paulo,  Brazil),  identiﬁed  by  the  acronym:  BHM-
CA;
Group  II:  PNs  fed  BHM  with  modiﬁed  HM  supplement:
100 mL  of  skimmed  HM,  evaporated  at  20%,  with  lactose
extraction  and  added  80  mL  of  pasteurized  HM,  identiﬁed
by  the  acronym:  BHM-E;
Group III:  PNs  fed  BHM,  with  modiﬁed  HM  supplement:
70 mL  of  skimmed  HM,  evaporated  at  20%,  with  lactose
extraction,  lyophilized,  reconstituted  in  100  mL  of  BHM  and
pasteurized,  identiﬁed  by  the  acronym:  BHM-L.
The  additives  obtained  from  HM  were  prepared  according
o the  method  described  by  Thomas  et  al.21
Of  the  24  PNs,  ten  belonged  to  GI,  ﬁve  to  GII,  and  nine
o GIII.  They  were  fed  according  to  this  order  at  different
imes. Although  selection  was  not  blinded,  all  PNs  who  met
he inclusion  criteria  and  who  were  hospitalized  during  the
tudy period  in  NHU-UFMS  were  selected  for  the  study.
The  PNs  included  in  the  study  had  gestational  age  <  34
eeks; birth  weight  ≤  1.500  kg,whether  or  not  adequate  for
estational age;  were  clinically  stable;  had  no  congenital
alformations; and  their  parents,  after  being  informed  of
he nature  of  the  study,  signed  the  informed  consent.
PNs  were  excluded  from  the  study  in  the  presence  of
ongenital malformations,  metabolic  disorders,  anemia,  any
ctive disease  (respiratory  disorders,  central  nervous  system
anifestations and  gastrointestinal),  periventricular  hem-
rrhage ≥  grade  2,  and  those  whose  mothers  had  sufﬁcient
ilk for  feeding.
During the  study,  PNs  that  presented  unfavorable  condi-
ions for  the  research  development  were  substituted;  these
onditions were  utterly  related  to  worsening  of  infection
evel.
The PNs  started  receiving  the  speciﬁc  diet  of  the  group
hey belonged  to  only  when  they  reached  full  (100  mL/kg)
nd well-tolerated  enteral  diet  and,  therefore,  the  PNs  were
nrolled in  the  study  as  soon  as  they  started  enteral  feeding
y gavage.
The PNs  were  followed  since  they  startedreceiving  the
odiﬁed milk  for  15  ±  2  days.
Non-blinded  analysis  of  levels  of  the  amino  acid  phen-
lalanine in  plasma  was  performed.  For  the  analysis,  a
re-prandial venous  sample  was  collected  (2.5  to  3  hours
fter the  last  feeding)  by  percutaneous  puncture  with  a
yringe containing  three  drops  of  heparin  (anticoagulant
ffect), packaged  in  a  microfuge  tube  (Eppendorf  do  Brasil
tda, São  Paulo,  Brazil).The  plasma  was  then  separated
y centrifugation  (2,500  rpm  for  10  min),  identiﬁed,  and
rozen at  -20 ◦C  for  subsequent  amino  acid  analysis  by  high
erformance liquid  chromatography.  Blood  collection  was
erformed in  each  child  of  the  three  groups  for  compari-
on of  the  amino  acid  proﬁle  on  the  ﬁrst  day,  before  the
ewborns started  the  speciﬁc  group  diet,  and  on  the  last
ay they  received  this  diet.
The  evaluation  of  the  association  between  diets
ffered to  the  PNs  with  the  variables  gender,  gestational
eight/age, and  RDS  was  performed  using  the  chi-squared
est. The  association  between  diets  offered  to  the  PNs  and
he variables  gestational  age,  birth  weight,  early  feeding,
olume, calories,  early  minimal  enteral  nutrition,  days  of
a
t
<
techanical  ventilation,  and  plasma  levels  of  phenylalanine
as performed  by  one-way  ANOVA,  followed  by  Tukey’s  post-
est. The  results  of  the  other  variables  assessed  in  this
tudy were  shown  as  descriptive  statistics  or  in  tables  and
harts. Statistical  analysis  was  performed  using  SPSS  soft-
are program,  release  20.0  (IBM  Corp,  NY,  USA),  considering
 signiﬁcance  level  of  5%.
esults
he  characteristics  of  the  three  groups  regarding  gender,
estational age,  birth  weight,  adequate  weight  for  gesta-
ional age,  early  minimal  enteral  feeding,  early  full  enteral
eeding, use  of  mechanical  ventilation,  respiratory  distress
yndrome, mean  volume,  and  calories  received  in  the  daily
iet are  shown  in  Table  1.
Regarding  these  characteristics,  the  groups  showed  no
igniﬁcant differences  (Table  1).
Plasma  levels  of  the  amino  acid  phenylalanine  (mean  ±
EM) in  the  ﬁrst  and  second  analysis  were,  respectively:  11.9
 1.22  and  29.72  ±  0.73  mol/L  in  Group  I (BHM-CA);  11.72
 1.04  and  13.44  ±  0.61  mol/L  in  Group  II  (BHM-E);  and
1.3 ±  1.18  and  15.42  ±  0.83  mol/L  in  Group  III  (BHM-
). The  results  regarding  the  concentration  of  the  essential
mino acid  phenylalanine  in  Groups  I,  II,  and  III  are  shown
n Fig.  1.
There was  no  difference  between  treatments  in  relation
o plasma  levels  of  phenylalanine  on  the  ﬁrst  day  of  full
nteral feeding  (one-way  ANOVA,  p  =  0.931).  Conversely,
he treatments  showed  differences  15  days  after  the  start
f feeding  (one-way  ANOVA,  p  <0.001),  with  plasma  phenyl-
lanine levels  in  the  group  of  PNs  fed  BHM-CA  higher  than
hat for  the  groups  BHM-E  and  BHM-L  (Tukey’s  post-test,  p
0.05), albeit  with  no  signiﬁcant  differences  between  the
wo latter  groups  (p  >  0.05).
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Table  1  Results  for  the  variables  assessed  in  this  study,  according  to  the  feedingtype  offered  to  preterm  newborns.
Variable  Treatment  p-valuea
GI  (BHM-CA) GII  (BHM-E)  GIII  (BHM-L)
Gender
Female  40.0  (4)  40.0  (2)  66.7  (6)  0.449
Male  60.0  (6) 60.0 (3)  33.3  (3)
Gestational age  (weeks) 30.20±0.36 30.00±1.30 26.56±2.96 0.345
Birth weight,  g 1,104.50±45.89 1,126.00±98.32 989.44±72.57 0.327
Classiﬁcation  (weight/  gestational  age)
AGA  90.0  (9)  100.0  (5)  88.9  (8)  0.748
SGA  10.0  (1)  0.0  (0)  11.1  (1)
Early feeding  (days  of  life)  17.70±3.68  14.20±2.87  17.00±2.15  0.776
Volume  (mL/kg/day)  167.72±8.52  166.49±5.19  166.18±9.25  0.976
Calories/kg/day  136.94±6.96  111.72±7.07  120.10±6.68  0.067
Early  minimal  enteral  nutrition  (days)  3.10±0.66  5.80±1.93  5.00±1.79  0.416
Mechanical  ventilation  (days)  9.80±3.12  5.00±1.96  12.44±2.96  0.296
RDS
Yes  80.0  (8)  100.0  (5)  100.0  (9)  0.217
No  20.0  (2)  0.0  (0)  0.0  (0)
The results are shown as mean ± standard error of the mean or relative frequency (absolute frequency).
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aRDS, respiratory distress syndrome; AGA, appropriate for gestatio
a p-value in the one-way ANOVA (gestational age, birth weight, 
and mechanical ventilation) or chi-squared test (gender, weight/g
Discussion
It  is  suggested  that  blood  samples  should  be  collected
immediately before  feeding  when  analyzing  the  amino  acid
proﬁle, so  they  can  be  analyzed  with  less  interference  from
the diet  offered.  This  evidence  justiﬁes  the  choice  of  per-
forming the  pre-prandial  collection  of  blood  for  amino  acid
analysis.22
When  phenylalanine  levels  were  compared  between  PNs
fed different  diets,  it  was  observed  that  those  fed  commer-
cial additives  had  higher  plasma  levels  of  this  amino  acid,
with a  signiﬁcant  difference  when  compared  to  those  fed
the evaporated  and  lyophilized  additives.
Considering  that  the  groups  were  similar  regarding  the
characteristics shown  in  Table  1  and  that  the  plasma  phen-
ylalanine levels  were  similar  in  the  three  groups  at  baseline,
this difference  in  phenylalanine  levels  at  the  end  of  the
study seems  to  be  related  to  the  quality  of  the  protein  in
the additive  used  by  each  group  and  the  lower  degradation
capacity of  this  amino  acid  in  PNs  compared  to  full-term
newborns. The  difference  should  not  be  associated  to  the
total amount  of  protein  consumed,  as  the  mean  protein
content of  the  diet  in  the  BHM-CA  group  (1.96  ±  0.01  g/dL)
is intermediate  to  those  in  groups  BHM-E  (1.81  ±  0.01  g/dL)
and BHM-L  (2.38  ±  0.03  g/dL).21
Although  the  caloric  value  of  BHM-CA  (81.65  ±
0.87 kcal/dL)  is  greater  than  that  of  BHM-E  (67.78  ±
2.01 kcal/dL)  and  BHM-L  (72.27  ±  2.56  kcal/dL),  a  still
unpublished clinical  study  observed  that  weight  and  length
gain was  similar  in  the  three  groups,  with  the  advantage  of
increased head  circumference  in  the  BHM-L  group  in  relation
to the  others.21 These  growth  characteristics  show  the  good
use of  protein  offered  by  homologous  additives  in  compari-
son to  the  commonly  used  commercial  additive.
p
a
gge; SGA, small for gestational age.
 of feeding, volume, calories, start of minimal enteral nutrition,
ional age classiﬁcation, RDS).
Studies evaluating  the  amino  acid  blood  proﬁle  of  PNs
ed HM  with  the  commercial  additive  FM85®  observed  that
etter adequacy  of  the  protein  supplied  by  this  supplement
s necessary.  The  additive  of  heterologous  origin  resulted  in
iochemical macronutrient  alterationsthat  may  affect  the
hildren’s neurodevelopment.23,24
When  analyzing  plasma  phenylalanine  levels  in  groups
f healthy  newborns  at  6  months  fed  breast  milk,  regu-
ar formula,  two  types  of  formulas  with  hydrolyzed  casein,
nd formulas  with  hydrolyzed  whey  protein,  the  group  fed
reast milk  had  the  lowest  levels  of  the  amino  acid,25 which
ppears to  occur  even  in  full-term  newborns,  due  to  the
igher content  of  phenylalanine  in  formulas  based  on  cow’s
ilk.
The same  result  was  found  in  PNs  fed  HM  with  three  dif-
erent additives:  HM  protein,  cow’s  milk  whey  protein,  and
 mixture  of  cow’s  milk  whey  protein,  peptides,  and  amino
cids, with  an  amino  acid  composition  similar  to  that  of  HM.
henylalanine levels  were  higher  in  the  group  who  received
M with  cow’s  milk  whey  protein  additive.  The  other  two
roups showed  no  differences.26
Additionally,  in  PNs  grouped  according  to  gestational  age
nd fed  HM  or  four  types  of  formula  with  protein  extracted
rom cow’s  milk  with  different  levels  and  proportion  of  whey
rotein/casein, those  fed  HM  showed  lower  plasma  levels  of
henylalanine.27
Conversely,  a  study  that  offered  PNs  BHM,  BHM  evapo-
ated at  70%,  or  BHM  with  the  commercial  additive  FM85®
ound no  signiﬁcant  differences  in  plasma  levels  of  phenyl-
lanine. In  this  case,  neither  the  quantity  nor  the  quality  of
rotein offered  had  an  effect  on  serum  levels  of  this  amino
cid.23
A  study  evaluating  the  concentrations  of  the  amino  acids
lycine, leucine,  and  phenylalanine  in  PNs  on  parenteral  and
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222  
nteral  nutrition  observed  that  the  concentrationsof  glycine
s more  affected  by  the  route  of  administration,  whereas
eucine is  little  affected,  and  phenylalanine  is  more  affected
y the  offered  supply.28
Despite  the  signiﬁcant  increase  in  plasma  phenylalanine,
o signiﬁcant  metabolic  effects  were  observed  in  babies  fed
ovine protein  during  the  study;  however,in  the  long  term,  it
an be  a  negative  factor  for  cognitive  development.  There-
ore, the  optimal  plasma  levels  of  phenylalanine  in  order  to
void effects  on  cognitive  development  in  the  long  term  are
till questioned.
This investigation  demonstrated  that  the  HM  with  its  own
dditives acted  as  a  good  substrate  to  feed  PNs,  whether  in
he evaporated  or  lyophilized  forms,  without  leading  to  sig-
iﬁcant increases  in  plasma  phenylalanine  when  compared
o HM  with  commercial  additive.
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